Clovis Oncology (CLVS) Posts Q2 Loss of 61c/Share, Narrower than Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St on pace for higher open as oil pulls back ahead of Fed decision
- Nvidia to commit $3 bln to Meta share offering as part of bigger AI partnership
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Boeing free cash flow beats estimates despite production challenges
Tweet
Share
E-mailGet Alerts CLVS Hot Sheet
Join SI Premium – FREE
Clovis Oncology (NASDAQ: CLVS) reported Q2 EPS of ($0.61), $0.09 better than the analyst estimate of ($0.70).
For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.
For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Corning shares rise 3% in premarket trade after Q3 EPS, revenue beat estimates
- Merck (MRK) Reiterated Neutral at by Cantor Fitzgerald
- Freeport-McMoran (FCX) Tops Q3 EPS by 8c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
